Posters

Comparison of efficacy and safety of dorzolamide: timolol maleate combination with oral acetazolamide for prevention of intraocular pressure rise following phacoemulsification surgery

Poster Details

First Author: S. Cetinkaya TURKEY

Co Author(s):                     

Abstract Details

Purpose:

To evaluate and compare the efficacy and safety of topical dorzolamide-timolol maleate combination with oral acetazolamide for prevention of intraocular pressure rise following phacoomulsification surgery.

Setting:

Turkish Red Crescent Hospital, Ophthalmology Clinics, Konya, Turkey

Methods:

67 eyes of 67 patients with cataract (33 males, 34 females) who had undergone phacoemulsification and IOL implantation surgery were evaluated retrospectively. Patients were divided into two groups. Group 1 comprised 33 (49%) patients who received oral acetazolamide 250 mg (Diazomid 250 mg tb) 1 hour before the surgery and 1hour after surgery and 125 mg 3 times a day for 3 days following surgery. Group 2 comprised 34 (51%) patients who received topical dorzolamide-tomolol maleate combination 1 drop 1 hour before the surgery and twice a day for 3 days following surgery.

Results:

The mean preoperative IOP of the first group was 14.60±3.21 (SD) (10-21) mmHg and that of the second group was 14.67±2.77 (SD) (11-21) mmHg (p=0.924). The mean postoperative IOP( 1st day) of the first group was 15.27±2.90 (SD) (11-23) mmHg and that of the second group was 14.82±2.57 (SD) (11-23) mmHg (p=0.505). The mean postoperative IOP (1st week) of the first group was 13.72±2.44 (SD) (10-18) mmHg and that of the second group was 13.64±2.53 (SD) (10-19) mmHg (p=0.895).

Conclusions:

For prophylaxis of postoperative IOP rise after an uneventful cataract surgery, topical-dorzolamid timolol maleate combination and oral acetazolamide therapy have similar effects, however the adverse effects of systemic acetazolamide should be taken into account, therefore it’s better to prefer topical dorzolamide-timolol maleate combination therapy.

Financial Disclosure:

None